These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 11374660

  • 1. Therapeutic equivalents in clinical practice.
    Benson MD.
    Int J Fertil Womens Med; 2001; 46(2):89-94. PubMed ID: 11374660
    [Abstract] [Full Text] [Related]

  • 2. The generics in transplantation and the rules on their use.
    Masri M.
    Exp Clin Transplant; 2003 Jun; 1(1):65-8. PubMed ID: 15859910
    [Abstract] [Full Text] [Related]

  • 3. Projecting future drug expenditures--1994.
    Santell JP.
    Am J Hosp Pharm; 1994 Jan 15; 51(2):177-87. PubMed ID: 8160668
    [Abstract] [Full Text] [Related]

  • 4. [Generic drug substitution].
    Tamir O, Halkin H, Shemer J.
    Harefuah; 2006 Sep 15; 145(9):691-5, 701. PubMed ID: 17078434
    [Abstract] [Full Text] [Related]

  • 5. When is a "generic" medication not really a generic?
    Howland RH.
    J Psychosoc Nurs Ment Health Serv; 2010 Feb 15; 48(2):13-6. PubMed ID: 20166651
    [Abstract] [Full Text] [Related]

  • 6. The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence.
    Duh MS, Cahill KE, Paradis PE, Cremieux PY, Greenberg PE.
    Expert Opin Pharmacother; 2009 Oct 15; 10(14):2317-28. PubMed ID: 19663636
    [Abstract] [Full Text] [Related]

  • 7. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT, Yang Y, Yu LX, Woodcock J.
    Ann Pharmacother; 2009 Oct 15; 43(10):1583-97. PubMed ID: 19776300
    [Abstract] [Full Text] [Related]

  • 8. United States Food and Drug Administration requirements for approval of generic drug products.
    Meyer MC.
    J Clin Psychiatry; 2001 Oct 15; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
    [Abstract] [Full Text] [Related]

  • 9. The rise of the generic drug market and its implications for dermatology.
    Bhosle M, Balkrishnan R, Dewan T, Yelverton CB, Feldman SR.
    J Dermatolog Treat; 2005 Oct 15; 16(5-6):295-8. PubMed ID: 16428148
    [Abstract] [Full Text] [Related]

  • 10. What makes a generic medication generic?
    Howland RH.
    J Psychosoc Nurs Ment Health Serv; 2009 Dec 15; 47(12):17-20. PubMed ID: 20000278
    [Abstract] [Full Text] [Related]

  • 11. Generic warfarin: implications for clinical practice and perceptions of anticoagulation providers.
    Bongiorno RA, Nutescu EA.
    Semin Thromb Hemost; 2004 Dec 15; 30(6):619-26. PubMed ID: 15630667
    [Abstract] [Full Text] [Related]

  • 12. FDA reform signed into law. Food and Drug Administration.
    James JS.
    AIDS Treat News; 1997 Dec 05; (No 284):6-7. PubMed ID: 11364915
    [Abstract] [Full Text] [Related]

  • 13. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J, Leong WL, Hoppensteadt DA, Jeske WP, Walenga J, Wahi R, Bick RL.
    Semin Thromb Hemost; 2004 Dec 05; 30(6):703-13. PubMed ID: 15630677
    [Abstract] [Full Text] [Related]

  • 14. Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals.
    Andersson K, Bergström G, Petzold MG, Carlsten A.
    Health Policy; 2007 May 05; 81(2-3):376-84. PubMed ID: 16945449
    [Abstract] [Full Text] [Related]

  • 15. Status of generic substitution: problematic drug classes reviewed.
    Ross MB.
    Hosp Formul; 1989 Aug 05; 24(8):441-4, 447-9. PubMed ID: 10294356
    [Abstract] [Full Text] [Related]

  • 16. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
    Maddineni J, Walenga JM, Jeske WP, Hoppensteadt DA, Fareed J, Wahi R, Bick RL.
    Clin Appl Thromb Hemost; 2006 Jul 05; 12(3):267-76. PubMed ID: 16959680
    [Abstract] [Full Text] [Related]

  • 17. The Hatch-Waxman Act: balancing competing interests or survival of the fittest?
    Behrendt KE.
    Food Drug Law J; 2002 Jul 05; 57(2):247-71. PubMed ID: 12436990
    [No Abstract] [Full Text] [Related]

  • 18. Prescription for fairness: a new approach to tort liability of brand-name and generic drug manufacturers.
    Rostron A.
    Duke Law J; 2011 Feb 05; 60(5):1123-91. PubMed ID: 21365961
    [Abstract] [Full Text] [Related]

  • 19. Recent trends in brand-name and generic drug competition.
    Grabowski H, Long G, Mortimer R.
    J Med Econ; 2014 Mar 05; 17(3):207-14. PubMed ID: 24320785
    [Abstract] [Full Text] [Related]

  • 20. [Medical problems and risks of switching drugs according to legal requirements of drug discount contracts in Germany].
    Pruszydlo MG, Quinzler R, Kaltschmidt J, Haefeli WE.
    Dtsch Med Wochenschr; 2008 Jul 05; 133(27):1423-8. PubMed ID: 18592450
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.